A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers ...
Feb 18, 2021
0
12
Patients with indolent non-Hodgkin lymphomas (iNHL) report considerable psychological distress, according to a study published online Nov. 3 in The Oncologist.
Nov 21, 2023
0
1
About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to ...
Feb 26, 2015
0
8
Next-generation sequencing studies have in recent years revealed numerous recurrently mutated genes in chronic lymphocytic leukemia (CLL). These mutations are usually found in a relatively small percentage of cases and associated ...
Mar 3, 2023
0
86
The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Jan 24, 2023
0
3
Chronic lymphocytic leukemia (CLL) is one of the most common blood cancers in adults. The disease originates in B cells—the part of the immune system that produces antibodies—and then evolves slowly, typically affecting ...
Apr 21, 2022
0
38
(HealthDay)—Venetoclax (VENCLEXTA) has been approved to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, the U.S. Food and Drug Administration announced yesterday.
May 17, 2019
0
1
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James), may offer a new treatment option ...
Nov 6, 2023
0
37
Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic ...
Jul 27, 2012
0
0
Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.
Jan 22, 2014
0
0
